Table 4. Multivariate (final) Cox proportional hazards model with left truncation assessing the impact of lenalidomide treatment and baseline factors on AML progressiona.
| Variable |
AML progression |
|
|---|---|---|
| HR (95% CI) | P-value | |
| Lenalidomide-treated vs untreated cohort | 0.969 (0.483–1.945) | 0.930 |
| Cytogenetic complexity (del(5q) plus >1 abnormality vs isolated) | 3.555 (1.576–8.022) | 0.002 |
| Cytogenetic complexity (del(5q) plus 1 abnormality vs isolated) | 1.095 (0.567–2.114) | 0.786 |
| Bone marrow blast count (5–10% vs <5%) | 2.158 (1.133–4.098) | 0.019 |
| RBC transfusion burden, units/8 weeks | 1.090 (1.003–1.185) | 0.041 |
| Hemoglobin level, g/dl | 0.861 (0.736–1.006) | 0.059 |
a
Lenalidomide treatment, although not significant in the univariate models, was forced to remain in the final models to estimate the magnitude of risk associated with lenalidomide in the presence of other risk factors. Complete covariate data were available for 243 of the lenalidomide-treated patients and 98 of the untreated patients.